CMS’ Amyvid Final NCD Clarifies Trial Outcomes Goals
This article was originally published in The Pink Sheet Daily
Agency’s final national coverage determination for beta amyloid positron emission tomography in diagnosing dementia confirms stance the diagnostic will be covered only in trial setting for Medicare, but may offer a little more flexibility in trial design.
You may also be interested in...
But appointment unlikely to signal new emphasis on prescription drugs for MedCAC.
Surprise provision directs favorable Medicare Part B reimbursement for a handful of therapeutics beginning later this year.
“Improvement in health outcomes” standard would interpret “the statute to require both diagnosis and treatment,” Lilly says about CMS’ recent evaluation of beta-amyloid positron emission tomography in dementia and neurodegenerative disease.